Prof. Bhargava has developed a digital method for identifying areas of early stage tumor and distinguishing them from benign population in breast cancer lesions. This...
Prof. Bhargava has developed a digital method for identifying areas of early stage tumor and distinguishing them from benign population in breast cancer lesions. This highly accurate artificial intelligence method can assist pathologists to interpret biopsies in breast cancer screening, increasing their efficiency and accuracy. About a million breast biopsies are performed in the US, out of which quarter receive a cancer diagnosis. The remaining patient cases are categorized by pathologists according to a diagnostic spectrum ranging from benign to preinvasive diseases which are difficult to classify. Misclassification can contribute to over treatment or undertreatment of lesions causing serious health and financial repercussions. Precise stratification of the lesions will reduce under or over diagnosis and time in breast cancer diagnosis.
This digital toolbox will be of interest to both health care clinics for risk stratification and early detection and digital pathology companies as a translatable diagnostic suite.
Professor Harley from the University of Illinois and his collaborators have developed a unique bioactive composite structure for use in the regenerative repair of...
Professor Harley from the University of Illinois and his collaborators have developed a unique bioactive composite structure for use in the regenerative repair of craniomaxillofacial bone injuries. This bioactive composite material is based on a 3D-printable foam which can be generated to fit complex shapes, features mechanical properties that can be tailored to match the physical properties of the bone at the surgical site, and can maintain their physical properties after being further shaped intraoperatively. When included within the bioactive composite structure this modular fiber mesh both passively aids surgical-practicality and actively accelerates regenerative healingreinforcement. More specifically, these bioactive composites supported human bone-marrow derived mesenchymal stemcell osteogenesis and new bone formation.Importantly, this bioactive composite does not suffer from the drawbacks of autologous bone or alloplastic implants, the current clinical gold standard for repair. Moreover, unlike current biomaterials this biomaterial composite has not demonstrated the release of any negative degradation by products, such as metal ions or acids.
